tetano
Editor, Senior Moderator
Cureus
. 2021 Sep 27;13(9):e18317.
doi: 10.7759/cureus.18317. eCollection 2021 Sep.
COVID-19 Coronavirus-Induced Atypical Pneumonia: Efficacy of the Monoclonal Antibody Bevacizumab in Moderate to Severe Cases
Greshaben Patel[SUP] 1 [/SUP], David Pielykh[SUP] 2 [/SUP], Sweetyben M Patel[SUP] 2 [/SUP], Meet J Patel[SUP] 3 [/SUP], Kaushal Bhavsar[SUP] 4 [/SUP], Thoyaja Koritala[SUP] 5 [/SUP]
Affiliations
Abstract
COVID-19 novel coronavirus has created a global pandemic. Affected patients may develop acute lung injury and its more severe form - acute respiratory distress syndrome. Hypoxia and severe inflammation increase the production of vascular endothelial growth factor (VEGF), which induces vascular endothelial proliferation. Administration of the anti-VEGF monoclonal antibody bevacizumab is proposed for usage in moderate to severe pneumonia. We aim to present two cases of COVID-19 induced atypical pneumonia, which were treated with the anti-VEGF monoclonal antibody bevacizumab.
Keywords: acute respiratory distress syndrome; angiogenseis; atypical pneumonia; bevacizumab; covid-19 pandemic; hypoxia.
. 2021 Sep 27;13(9):e18317.
doi: 10.7759/cureus.18317. eCollection 2021 Sep.
COVID-19 Coronavirus-Induced Atypical Pneumonia: Efficacy of the Monoclonal Antibody Bevacizumab in Moderate to Severe Cases
Greshaben Patel[SUP] 1 [/SUP], David Pielykh[SUP] 2 [/SUP], Sweetyben M Patel[SUP] 2 [/SUP], Meet J Patel[SUP] 3 [/SUP], Kaushal Bhavsar[SUP] 4 [/SUP], Thoyaja Koritala[SUP] 5 [/SUP]
Affiliations
- PMID: 34725588
- PMCID: PMC8553284
- DOI: 10.7759/cureus.18317
Abstract
COVID-19 novel coronavirus has created a global pandemic. Affected patients may develop acute lung injury and its more severe form - acute respiratory distress syndrome. Hypoxia and severe inflammation increase the production of vascular endothelial growth factor (VEGF), which induces vascular endothelial proliferation. Administration of the anti-VEGF monoclonal antibody bevacizumab is proposed for usage in moderate to severe pneumonia. We aim to present two cases of COVID-19 induced atypical pneumonia, which were treated with the anti-VEGF monoclonal antibody bevacizumab.
Keywords: acute respiratory distress syndrome; angiogenseis; atypical pneumonia; bevacizumab; covid-19 pandemic; hypoxia.